Smokeless oral nicotine products could impact heart health

Investigators have outlined the potential cardiovascular risks of smokeless oral nicotine products.

In a policy statement by the American Heart Association, published in Circulation, the investigators detailed that patients with ischemic heart of cerebrovascular disease may have a heightened risk of mortality when using smokeless oral nicotine products. Those who use smokeless tobacco may be more likely to develop oral cancer.

In addition, newer tobacco-free oral nicotine products such as oral nicotine pouches; nicotine gummies and nontherapeutic nicotine fumes, lozenges and tablets as well as synthetic oral nicotine products have become available with little or no information on their cardiovascular risks.

The AHA identified several policies initiatives and interventions that could reduce cardiovascular risks and addiction among those using smokeless oral nicotine products — including flavor restrictions, marketing regulations, taxation strategies and pharmacologic and behavioral tobacco dependence treatment therapies.

Read more: Circulation

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.